"immune checkpoint receptors" trang 8 - tải miễn phí từ tailieunhanh
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer
10    19    1
Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer
11    15    1
Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer

Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer
8    17    1
Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: A case report

Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: A case report
8    1    1
A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: A case report

A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: A case report
4    1    1
Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: A case report

Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: A case report
6    1    1
Steven-Johnson syndrome: A rare but serious adverse event of nivolumab use in a patient with metastatic gastric adenocarcinoma

Steven-Johnson syndrome: A rare but serious adverse event of nivolumab use in a patient with metastatic gastric adenocarcinoma
7    6    1
SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
12    1    1
Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma

Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma
12    1    1
Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
14    1    1
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy

Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
14    1    1
PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: A single institution experience

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: A single institution experience
6    1    1
Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab

Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
7    1    1
Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: A retrospective study

Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: A retrospective study
13    1    1
Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: A meta-analysis

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: A meta-analysis
16    1    1
Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A prospective, Single-Arm, phase II trial

Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A prospective, Single-Arm, phase II trial
10    2    1
Clinical markers of immunotherapy outcomes in advanced sarcoma

Clinical markers of immunotherapy outcomes in advanced sarcoma
8    4    1
Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer

Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer
15    7    1
CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer

CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer
8    5    1
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: A multicenter retrospective cohort study

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: A multicenter retrospective cohort study
10    6    1